Exploring new cancer treatments using iron-activated drugs
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer
This study is exploring new cancer treatments that use iron to help special drugs target and kill cancer cells more effectively, especially for patients with aggressive tumors linked to the KRAS gene, while trying to keep healthy cells safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11143196 on NIH RePORTER |
What this research studies
This research investigates innovative cancer therapies that utilize iron to activate specific drugs targeting cancer cells. By focusing on the unique way cancer cells handle iron, the study aims to develop new treatments that can selectively kill cancer cells while minimizing harm to healthy cells. The approach involves creating drug conjugates that are activated in the presence of labile iron, which is found in higher concentrations in cancer cells. This method seeks to improve the effectiveness of existing cancer treatments, particularly for aggressive tumors driven by mutations in the KRAS gene.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with cancers driven by KRAS mutations or those who have not responded well to traditional therapies.
Not a fit: Patients with cancers that do not involve the RAS MEK ERK pathway or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments that specifically target malignant cells.
How similar studies have performed: Other research has shown promise in targeting cancer cells through similar mechanisms, suggesting that this approach could be a viable new treatment strategy.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Collisson, Eric — Fred Hutchinson Cancer Center
- Study coordinator: Collisson, Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.